The treatment of dysmenorrhea with naproxen sodium: a report on two independent double-blind trials.
The efficacy of naproxen sodium (naproxen-Na) in dysmenorrhea has been established in two independent double-blind (placebo-controlled) studies. An initial dose of 550 mg. of naproxen-Na was followed by 275 mg. every six hours for a maximum of five days. Twenty patients were included in Study I (10 treated with naproxen-Na) and 23 patients in Study II (12 treated with naproxen-Na). Each patient received the medication during four dysmenorrheic episodes. Thus, a total of 172 treatment courses could be evaluated. A variety of efficacy criteria were measured: frequency of pill intake, changes in pain intensity, the degree of relief achieved by the medication, and need for additional analgesics. In both studies naproxen-Na was demonstrated to be superior to the placebo treatment with high statistical significance in each of these parameters.
D000328:Adult; D002986:Clinical Trials as Topic; D004412:Dysmenorrhea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009280:Naphthaleneacetic Acids / Q000627:therapeutic use*; D009288:Naproxen / Q000627:therapeutic use*; D010919:Placebos; D012964:Sodium / Q000627:therapeutic use
D009280:Naphthaleneacetic Acids; D010919:Placebos; D009288:Naproxen; D012964:Sodium